Blood Doping with erythropoitin improves an athlete's performance by which process?

Question

Accepted Answer

The correct option is (3):
Blood doping with erythropoietin (EPO) fundamentally causes a substantial increase in the production and count of Red Blood Cells (RBCs), which is the basis for improved oxygen transport. This massive increase in the cellular component of the blood directly and inevitably leads to a higher hematocrit (percentage of blood volume occupied by RBCs). The increase in hematocrit, in turn, raises the internal friction of the blood, dramatically increasing its viscosity—the physical process described as "thickening the blood." While the performance improvement is linked to oxygen delivery, the thickening is the biophysical state change that results from the necessary condition (excess RBCs) for that improvement, making it the most accurate description of the physical transformation of the blood, though it also represents the primary health risk.

The incorrect option is (2):
Increasing the number of RBC in the blood is, in a strictly physiological sense, the mechanism that leads to improved performance, as more RBCs equal greater oxygen-carrying capacity. However, in the context of describing the change in the *nature* of the blood as a fluid, increasing the number of cells is the *cause*, and the resulting *effect* on the blood's flow property is its thickening (increased viscosity). Therefore, while the RBC count is the root mechanism, the question may be focused on the final physical state of the blood, which is its abnormal thickness due to the high concentration of cells.

The incorrect option is (1):
Making blood circulate much faster is generally an inaccurate description of the effect of blood doping. The increased viscosity or "thickening" of the blood creates significantly more resistance to flow within the circulatory system. This increased resistance forces the heart to work much harder to maintain even a normal circulation rate. In fact, a dangerously high hematocrit can even slow circulation down, leading to stagnation and significantly increasing the risk of fatal events like stroke or heart attack, which is the exact opposite of circulating faster.

The incorrect option is (4):
Cooling the blood is not a process by which blood doping with erythropoietin improves performance. EPO is a hormonal drug that manipulates the bone marrow's production of blood cells, which is a chemical and physiological process, not a temperature-based one. Techniques like cooling the blood (therapeutic hypothermia) are sometimes used in emergency medicine to reduce metabolic demands, but they are completely unrelated to performance enhancement through blood doping.